FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue (methylthioninium chloride) and serotonergic psychiatric medications

This update is in follow-up to the FDA Drug Safety Communication posted on 7/26/2011: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications.

Safety Announcement

[10-20-2011] The U.S. Food and Drug Administration (FDA) is updating the public on the potential drug interaction between methylene blue and serotonergic psychiatric medications.

FDA is providing additional information about the reports of serotonin syndrome. Most cases from the FDA's Adverse Event Reporting System (AERS) of serotonin syndrome in patients given serotonergic psychiatric medications and methylene blue occurred in the context of parathyroid surgery, which involved the intravenous administration of methylene blue as a visualizing agent. Methylene blue doses ranged from 1 mg/kg to 8 mg/kg.

Because methylene blue is not an FDA-approved drug at this time, and limited data exist regarding its use in various settings, it is not known whether there is a risk of serotonin syndrome in patients taking serotonergic psychiatric medications who are given methylene blue by other routes (e.g., orally or by local tissue injection) or at intravenous doses lower than 1 mg/kg.

In addition, not all serotonergic psychiatric drugs have an equal capacity to cause serotonin syndrome with methylene blue. The cases of serotonin syndrome with methylene blue occurred in patients taking specific serotonergic psychiatric drugs, namely a selective serotonin reuptake inhibitor (SSRI), a serotonin norepinephrine reuptake inhibitor (SNRI), or clomipramine (see section I). It is unclear at this time whether intravenous methylene blue administration in patients receiving other psychiatric drugs with lesser degrees of serotonergic activity poses a comparable risk (see section II).

FDA will update the public when new information is available.

I. Serotonergic psychiatric drugs implicated in the AERS cases of serotonin syndrome with methylene blue

Selective Serotonin Reuptake Inhibitors

 Generic NameFound in Brand Names 
paroxetine      Paxil, Paxil CR
fluvoxamineLuvox, Luvox CR
fluoxetineProzac, Symbyax
vilazodone1  Viibryd

1 Although the FDA has not received cases of serotonin syndrome to date involving vilazodone, the pharmacology of this drug places it in the SSRI category and suggests that it possesses a risk comparable to that of the SSRIs. 

Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Generic NameFound in Brand Names
venlafaxineEffexor, Effexor XR


Tricyclic Antidepressants (TCAs)

Generic NameFound in Brand Names

II. Other psychiatric drugs with varying degrees of serotonergic activity for which the risk of serotonin syndrome with methylene blue is unclear

Tricyclic Antidepressants (TCAs)


Generic NameFound in Brand Names
amitriptyline                    Amitid, Amitril, Elavil, Endep, Etrafon, Limbitrol, Triavil
desipramineNorpramin, Pertofrane


Tofranil, Tofranil PM, Janimine, Pramine, Presamine


Pamelor, Aventyl hydrochloride
doxepinSinequan, Zonalon, Silenor 

Monoamine Oxidase Inhibitors (MAOIs) 

Generic NameFound in Brand Names
transdermal selegilineEmsam

Other Psychiatric Medications


   Generic Name           Found in Brand Names
trazodoneDesyrel, Oleptro, Trialodine
bupropionWellbutrin, Wellbutrin SR, Wellbutrin XL, Aplenzin
buspirone               Buspar
mirtazapine                Remeron, Remeron Soltab


Contact FDA

1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857

Page Last Updated: 12/11/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English